Drugs / NT100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02156063 | Jun 2014 → Jan 2016 | pregnancy loss, recurrent, 4 | Nora Therapeutics, Inc. | Unknown | Missed primary |
| Phase 2 | NCT01978561 | Oct 2013 → Aug 2015 | pregnancy loss, recurrent, 4 | Nora Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01864356 | May 2013 → Sep 2014 | pregnancy loss, recurrent, 4 | Nora Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NT100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01864356 ↗ |
| Route | Subcutaneous | “subcutaneous NT100” NCT01864356 ↗ |